AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

67.47USD
1:32am IST
Change (% chg)

$0.09 (+0.13%)
Prev Close
$67.38
Open
$67.40
Day's High
$67.52
Day's Low
$66.64
Volume
3,425,718
Avg. Vol
2,665,997
52-wk High
$70.76
52-wk Low
$51.40

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a global research-based pharmaceuticals company. The Company’s products are used to treat chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn’s disease; human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease, and complications associated with... (more)

Overall

Beta: --
Market Cap(Mil.): $107,341.50
Shares Outstanding(Mil.): 1,593.08
Dividend: 0.51
Yield (%): 3.03

Financials

  ABBV.N Industry Sector
P/E (TTM): 59.90 35.92 38.01
EPS (TTM): 1.12 -- --
ROI: 9.54 16.11 15.44
ROE: 59.80 16.90 16.48
Search Stocks

Borrowers warned: Don't be fooled by high grade market resilience

NEW YORK, May 11 (IFR) - Apple, Shell and AbbVie blitzed the US bond market last week with a combined US$34bn of jumbo bond deals in just two days, bringing the week's tally to US$52bn, the fourth-largest of all time.

11 May 2015

Drugmaker AbbVie's profit beats estimates on strong Humira sales

- U.S. drugmaker AbbVie Inc reported better-than-expected quarterly profit and revenue, driven by strong sales of its arthritis drug, Humira.

23 Apr 2015

Drugmaker AbbVie profit rises on sales of Humira

April 23 - U.S. drugmaker AbbVie Inc reported a 4 percent rise in quarterly profit, driven by strong sales of its arthritis drug, Humira.

23 Apr 2015

Fresenius CEO says to sit out healthcare deal wave

MUNICH - German healthcare group Fresenius will lie in wait for an overheated healthcare deal market to cool down before making further larger acquisitions, its chief executive said.

22 Apr 2015

Top Mylan shareholders seek deal with Teva - sources

- Some of the top investors at Mylan NV , including Paulson & Co, are encouraging its board of directors to consider a takeover proposal from rival Teva Pharmaceutical Industries Inc , according to people familiar with the matter.

22 Apr 2015

Top Mylan shareholders seek deal with Teva: sources

- Some of the top investors at Mylan NV, including Paulson & Co, are encouraging its board of directors to consider a takeover proposal from rival Teva Pharmaceutical Industries Inc, according to people familiar with the matter.

22 Apr 2015

BRIEF-Ablynx starts first of phase IIb rheumatoid arthritis study with Abbvie

* Ablynx initiates the first of two phase IIb RA studies with its anti-il-6r nanobody, partnered with Abbvie

17 Mar 2015

Pharmacyclics cancer drug successful as combination therapy: independent panel

- An independent panel recommended unblinding a late-stage study testing Pharmacyclics Inc and Johnson & Johnson's Imbruvica, after the treatment was successful against two similar forms of cancer in combination with other drugs.

17 Mar 2015

TRLPC: Abbvie and NXP boost M&A volumes

NEW YORK, March 12 - The loan market received another boost this week as drugmaker Abbvie and semiconductor company NXP boosted U.S. M&A volume to $152.7 billion so far this year, including completed and deals in the pipeline.

12 Mar 2015

AbbVie CEO defends Pharmacyclics deal to sceptical investors

NEW YORK - AbbVie Inc chief Richard Gonzalez fought two other drugmakers to "the bitter end" to buy Pharmacyclics Inc for its hot-selling Imbruvica cancer drug, but may have a harder time convincing investors it is worth $21 billion.

06 Mar 2015

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $101.15 +0.02
Pfizer Inc. (PFE.N) $34.44 +0.14
Novartis AG (NOVN.VX) CHF98.45 -0.05
Merck & Co., Inc. (MRK.N) $59.70 +0.24
Roche Holding Ltd. (ROG.VX) CHF282.50 +1.80
Abbott Laboratories (ABT.N) $49.26 +0.25
Eli Lilly and Co (LLY.N) $76.41 +1.51

Earnings vs. Estimates

Search Stocks